Pancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Pancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-07-21Clinical Trial Update: Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy [NA]
A completed clinical trial evaluating Roux-en-Y anastomosis of the pancreatic stump to prevent pancreatic fistula after distal pancreatectom…
-
CLINICAL_TRIALS trial_result · 2016-07-15Clinical Trial Update: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma [Phase 1]
Phase 1 clinical trial evaluating the combination of Cixutumumab, Everolimus, and Octreotide acetate in patients with advanced low- to inter…
-
CLINICAL_TRIALS trial_result · 2016-05-30Clinical Trial Update: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery [Phase 2]
Phase 2 trial evaluating the use of combination chemotherapy as first-line therapy for locally advanced or metastatic neuroendocrine tumors …
-
CLINICAL_TRIALS trial_result · 2016-05-03Clinical Trial Update: Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors [Phase 4]
Update on a Phase 4 trial assessing the diagnostic usefulness of serum chromogranin A for pancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. [Phase 2]
Phase II trial of BEZ235 (dactolisib) in advanced pancreatic neuroendocrine tumors after failure of mTOR inhibitor therapy has completed wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-04-07Clinical Trial Update: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial comparing BEZ235 (dactolisib) to Everolimus in advanced pancreatic neuroendocrine tumors was terminated, and results have been…
-
CLINICAL_TRIALS trial_result · 2016-02-18Clinical Trial Update: Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) [Phase 2]
Phase 2 study of the AKT inhibitor MK-2206 in patients with metastatic pancreatic neuroendocrine tumors; results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-02-11Clinical Trial Update: Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery [Phase 2]
Phase 2 trial evaluating everolimus with octreotide acetate with or without bevacizumab in locally advanced or metastatic pancreatic neuroen…
-
CLINICAL_TRIALS research · 2016-01-06Clinical Trial Update: Nonfunctional Pancreatic NET and PET Imaging [Phase 4]
Phase 4 clinical trial update focusing on nonfunctional pancreatic neuroendocrine tumors and PET imaging. The current status of the study is…
-
CLINICAL_TRIALS trial_result · 2015-12-08Clinical Trial Update: Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival
The clinical trial update discusses how surgical factors may influence survival in patients with pancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2015-11-06Clinical Trial Update: A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. [NA]
Continuation study of sunitinib malate for patients who left a prior sunitinib trial; completed with results posted in 2015.
-
FDA approval · 2015-11-02FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2015-08-06Clinical Trial Update: Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms [NA]
This completed trial compares robotic, laparoscopic, and open enucleation of benign pancreatic neoplasms. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2015-04-29Clinical Trial Update: An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
This clinical trial update analyzes how pancreatic neuroendocrine tumors present and the outcomes following treatment, with results posted i…
-
FDA approval · 2015-04-24FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals.
-
FDA approval · 2014-12-19FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2014-04-29Clinical Trial Update: Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Phase 1]
Phase 1 trial update of sorafenib in combination with RAD001 (everolimus) in patients with advanced neuroendocrine tumors, including carcino…
-
CLINICAL_TRIALS trial_result · 2014-04-21Clinical Trial Update: Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors [Phase 1]
Phase 1 dose-escalation study of TH-302 in combination with sunitinib for advanced renal cell carcinoma, gastrointestinal stromal tumors, an…
-
CLINICAL_TRIALS trial_result · 2014-01-17Clinical Trial Update: 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating 68Ga-DOTATATE PET imaging in patients with neuroendocrine tumors to assess diagnostic performance.
-
CLINICAL_TRIALS research · 2013-10-29Clinical Trial Update: Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
A clinical trial update discusses a disease-specific questionnaire used to assess quality of life in patients with gastrointestinal-related …
-
FDA approval · 2013-08-30FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
The FDA overview notes a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals. The submission status is …
-
CLINICAL_TRIALS trial_result · 2013-06-18Clinical Trial Update: Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial evaluating thalidomide in metastatic neuroendocrine tumors has completed, including gastrointestinal carcinoid tumors and panc…
-
FDA approval · 2012-08-29FDA Approved: AFINITOR DISPERZ — Original Application (Novartis Pharmaceuticals Corporation)
FDA approves AFINITOR DISPERZ (everolimus) under an Original Application for a dispersible tablet formulation.
-
FDA approval · 2012-06-28FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Meitheal Pharmaceuticals, Inc.)
The FDA approved a supplemental application for octreotide acetate from Meitheal Pharmaceuticals, authorizing a generic version of the drug.…
-
CLINICAL_TRIALS trial_result · 2012-03-30Clinical Trial Update: Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy [Phase 2]
Phase 2 trial results evaluating everolimus for adults with advanced pancreatic neuroendocrine tumors not responding to chemotherapy, assess…